Gemina Laboratories Ltd. (CNSX:GLAB) acquired 19% stake in Rapivd Limited for £0.52 million on December 7, 2022. As for consideration, £259,259 was paid in cash and Gemina Laboratories Ltd. issued 1,086,956 common shares. Gemina Laboratories Ltd. also has the option to purchase the remaining 81% of the RAPIvD. In connection with the Transaction, Robert Porter, the Chief Executive Officer of RAPIvD has agreed to join the board of Gemina Laboratories Ltd. All Gemina Shares issued in exchange for RAPIvD Shares pursuant to the Transaction will be subject to a statutory hold period of four months and one day from the date of issuance in accordance with applicable securities legislation.

Gemina Laboratories Ltd. (CNSX:GLAB) completed the acquisition of Rapivd Limited On December 7, 2022.